Learning Objectives:

  1. Evaluate the safety and efficacy of renal denervation (RDN) in patients already on antihypertensive medications. 
  2. Critically analyze the results of the SPYRAL HTN-ON MED trial, focusing on primary and secondary efficacy outcomes.
Session date: 
03/22/2024 - 7:30am to 8:30am CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Dr. Nso Nso